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Abstract
Background: Point mutations in genes encoding NADP+-dependent isocitrate dehydrogenases (especially IDH1)
are common in lower grade diffuse gliomas and secondary glioblastomas and occur early during tumor
development. The contribution of these mutations to gliomagenesis is not completely understood and research is
hampered by the lack of relevant tumor models. We previously described the development of the patient-derived
high-grade oligodendroglioma xenograft model E478 that carries the commonly occurring IDH1-R132H mutation.
We here report on the analyses of E478 xenografts at the genetic, histologic and metabolic level.
Results: LC-MS and in situ mass spectrometric imaging by LESA-nano ESI-FTICR revealed high levels of the
proposed oncometabolite D-2-hydroxyglutarate (D-2HG), the product of enzymatic conversion of α-ketoglutarate
(α-KG) by IDH1-R132H, in the tumor but not in surrounding brain parenchyma. α-KG levels and total NADP+-dependent
IDH activity were similar in IDH1-mutant and -wildtype xenografts, demonstrating that IDH1-mutated cancer cells
maintain α-KG levels. Interestingly, IDH1-mutant tumor cells in vivo present with high densities of mitochondria and
increased levels of mitochondrial activity as compared to IDH1-wildtype xenografts. It is not yet clear whether this
altered mitochondrial activity is a driver or a consequence of tumorigenesis.
Conclusions: The oligodendroglioma model presented here is a valuable model for further functional elucidation of
the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic
strategies for the large subgroup of gliomas carrying IDH1 mutations.
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Background
Diffuse gliomas are notoriously difficult to treat, and re-
main incurable to this date. Based on WHO guidelines,
these tumors are categorized in grade II-IV, grade IV
(glioblastoma) being the most aggressive subtype [1].
Grade IV gliomas may develop de novo (primary glio-
blastoma) or evolve from lower grade tumors (secondary
glioblastoma) [2-5]. The role of specific tumor suppres-
sor genes and oncogenes in gliomagenesis has rapidly
been elucidated in the last decades [6-12]. A recent
breakthrough was the discovery of the involvement of
mutations in the genes for isocitrate dehydrogenase 1
(IDH1) and, less frequently, IDH2 [13-15] in grade II/III
gliomas and secondary glioblastomas. IDH mutations are
uncommon in other tumor types, with the exception of
acute myeloid leukemia (AML), angioimmunoblastic T-
cell lymphomas, intrahepatic cholangiocarcinomas and
chondrosarcomas [13,16-19]. Mutations in glioma al-
most always involve an arginine-to-histidine conversion
at position 132 in the catalytic site of IDH1 [14,20,21].
The high frequency of mutations in IDH1 suggests an
important role for the mutant protein in early glioma
development, but the exact underlying oncogenic mech-
anism is not completely understood. IDH1 is a cytoplas-
mic enzyme that converts isocitrate to α-ketoglutarate
(α-KG), with simultaneous reduction of NADP+ to
NADPH [22]. The other family members IDH2 and −3
reside in mitochondria and are either NADP+- (IDH2) or
NAD+-dependent (IDH3). For as yet unknown reasons, the
occurrence of IDH mutations in glioma is restricted to the
NADP+ dependent variants [23].
The R132H mutation equips the enzyme with a
neomorphic activity resulting in a reduction of α-KG to
D-2-hydroxyglutarate (D-2HG) [24], an NADPH con-
suming process. D-2HG may be an ‘oncometabolite’, but
whether and how it contributes to gliomagenesis is a
matter of debate. Patients with D-2-hydroxyglutaric
aciduria, a rare metabolic condition in which high levels
of D-2HG occur due to mutations in the D-2HG
dehydrogenase gene D2HGDH or in IDH2, do not show
increased levels of tumor development [25]. Paradoxically,
the metabolic condition L-2-hydroxyglutaric aciduria has
been suggested to predispose for brain tumorigenesis
[26,27]. Depletion of α-KG, an essential citric acid cycle
intermediate, in IDH1 mutant tumor cells may play a role
during tumor development [28] but competitive inhibition
by D-2HG of the 60 known α-KG-dependent enzymes
appears to be a more important factor [29]. For ex-
ample, inhibition of α-KG-dependent TET2 and histone
demethylase KDM4C (also known as JMJD2C) results
in DNA hypermethylation and histone demethylation
respectively and, as a result, blocks cell differentiation
[30-32]. Furthermore, increased degradation of hypoxia-
inducible factor 1α (HIF1α) via inhibition of α-KG
dependent EGLN prolyl 4-hydroxylases may play a role
[33]. Recently, it was described that this mechanism con-
tributes to leukemogenesis in a reversible manner [34].
IDH1 mutations nearly always occur in a heterozygous
fashion and the presence of a wild type (wt) allele is
required for the maximal neomorphic activity of the mu-
tant protein [35]. The enzyme consists of two independ-
ently acting subunits. Wild type enzyme subunits, either
as homodimer or in mutant/wt heterodimers, convert
isocitrate to α-KG which is subsequently processed by the
mutant enzyme (subunits) to D-2HG [36]. Whereas
wtIDH1 can convert α-KG back to isocitrate in a CO2-
and NADPH-dependent manner, this activity is lost by the
R132 mutation [22]. The stoichiometry of IDH1 wt and
mutant proteins is likely an important parameter which
determines α-KG and D-2HG levels and may therefore in-
fluence cell metabolism [35]. Therefore, it is not clear to
what extent exogenous introduction of recombinant mu-
tant IDH1 in cell lines provides relevant information as
overexpression may result in a non-physiological amount
of IDH1-mutant homodimers which may differ in activity
from heterodimers [37]. Moreover, metabolism of cells
under standard culture conditions may significantly differ
from in vivo conditions where local areas of hypoxia and
hypoglycemia routinely occur. Therefore, it is important
to study relevant orthotopic glioma xenograft models
that recapitulate the biology of tumors carrying the en-
dogenous mutation. It has been shown by several
groups that gliomas with IDH1 mutations are difficult,
if not impossible, to culture and propagate in vitro
under standard serum-free or serum-containing culture
conditions [38-40]. Similarly, in vivo models are difficult
to propagate and as a result, preclinical glioma models
carrying the IDH1 or IDH2 mutation are scarce.
Here, we report on the genetic, histologic and meta-
bolic characterization of the E478 human oligodendro-
glioma xenograft line which carries the endogenous
heterozygous IDH1-R132H mutation and provide novel
insight into the metabolism of these tumors.
Results
Development of IDH1-R132H xenografts
In our institute, we have a long history of developing
patient-derived orthotopic glioma xenograft models by
direct intracerebral implantation of cancer cell suspen-
sions from surgically-obtained glioma specimens [41].
As long-term in vitro cell cultures are known to be gen-
etically unstable [42], the development of such direct
orthotopic xenografts is important in the context of clin-
ical relevance and reproducibility. Remarkably, from 5
biopsies derived from IDH1-R132H-mutated high-grade
oligodendroglioma specimens only one so far gave rise
to the stable xenograft line described here (E478). This
is in line with a previous report which demonstrated that
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xenografting of cultured IDH1 mutant glioma cells
hardly results in in vivo tumor growth [38] and is in
sharp contrast with our experience with orthotopic
xenografting of IDH1wt gliomas in which success rates
approach 100%. Attempts to culture E478 cells in vitro
using both neurosphere and standard culture conditions
were so far unsuccessful (data not shown). Occasionally,
we managed to maintain short-term organotypic spher-
oid cultures [43] and these were used for genetic ana-
lyses (Additional file 1 and Additional file 2: Figure S1).
To increase the versatility of the E478 model, we gen-
erated cell suspensions directly from xenografts and
cryopreserved these before re-injecting them intracere-
brally in mice. This procedure resulted in successful
orthotopic engraftment in 100% of the animals, also after
re-transplantation.
The E478 xenograft model has now been maintained
in the brains of Balb/c nu/nu mice by serial transplant-
ation for over 32 passages (P) in a period of over 8 years.
PCR sequencing of IDH1 confirmed the maintenance of
the heterozygous c.395G > A mutation [NM_005896.2]
resulting in the R132H conversion in IDH1 (Figure 1A),
similarly to the parental tumor (data not shown). Cyto-
plasmic expression of the mutant IDH1 protein was
readily detected in E478 xenografts using IHC and a
monoclonal antibody that specifically recognizes the
R132H mutated IDH1 protein [44] (Figure 1B). Tumor
take of E478 xenografts after intracerebral passaging is
over 95% and the median time until mice are sacrificed
because of tumor-related symptoms is 78 days (n = 200,
P 0, 10 and 20 shown in Figure 1C).
Genetic analysis of E478 xenografts
To compare the chromosomal aberrations in the E478
xenografts and the parental tumor, we performed array
comparative genomic hybridization (aCGH) analyses
(Figure 1D). The original tumor showed complete hemi-
zygous loss of chromosomal arms 1p and 19q, a charac-
teristic feature of oligodendroglial tumors. Additionally,
hemizygous losses of chromosomes 4, 9 as well as
B CA
Xenograft, P25
patientD
0 25 50 75 100 125 150
0
25
50
75
100
P0
P10
P20
P30
Time (days)
Su
rv
iv
a
l p
ro
ba
bi
lit
y 
(%
)
Figure 1 E478 xenografts contain the IDH1-R132H mutation. A) E478 xenografts contain the G=> A mutation as shown by direct
sequencing. B) Micrograph of a E478 xenograft in mouse brain, stained with the IDH1-R132H-specific antibody, bar =100 μm. C) Curves of time to
sacrifice of mice in various passages of the E478 line, P0 being the first transplantation of surgically-obtained tumor material, directly from the
patient in nude mice. D) Comparison of array CGH profiles of the tumor of the patient (blue) and a derived xenograft (P25, brown). The losses of
chromosome arms 1p and 19q, typical for oligodendroglioma, are indicated by arrows in the profile of the patient tumor. All genetic aberrations
that were present in the original tumor, are present in the profile of the xenografts as well, with a few additional aberrations in the xenograft.
Further details are presented in Additional file 2: Figure S1.
Navis et al. Acta Neuropathologica Communications 2013, 1:18 Page 3 of 12
http://www.actaneurocomms.org/content/1/1/18
13q21.33-31.2 were detected. A region in chromosome 4
(59.5-62.2 Mb), which is devoid of any known genes or
miRNAs, was homozygously deleted. Furthermore, the
tumor was triploid for 7p15.2-qter, 8q12.3-qter and 11
(Figure 1D, upper panel). All aberrations were maintained
in late passages (Figure 1D, lower panel). Some additional
aberrations were also detected in the xenograft, including
loss of 2q22-qter, 3pter-p21.2, chromosomes 10, 12 and
18 as well as gains of chromosome 21 (Additional file 2:
Figure S1). Glial tumors show a high level of intratumoral
genomic heterogeneity [45] which might explain the dif-
ferences observed between the original tumor biopsy and
its derived xenograft.
We determined the DNA quantity per cell of the
xenograft tumor by flow cytometry of DAPI-labeled nu-
clei (Additional file 3: Figure S2A). A minor fraction of
the cells appeared to be diploid and was considered to
consist of stromal or host-derived cells. The majority of
cells were aneuploïd with a DNA index of 1.925, which
corresponds to 3.85 N. The xenograft tumor thus has a
near tetraploïd genome with some xenograft-specific
losses. The inferred copy number at the IDH1 locus on
2q34 is 3.
In order to determine the genotype at the IDH1 locus,
we set up an allele-specific TaqMan SNP genotyping
assay that can discriminate between the wild type and
R132H alleles of IDH1. This assay revealed that the
R132H allele was twice more abundant than the wt allele
in the xenograft (Additional file 1 and Additional file 3:
Figure S2B), resulting in an IDH1R132H/R132H/WT genotype
in the xenograft.
Phenotype of the E478 xenografts
E478 xenografts characteristically grow to diffuse infiltrative
tumors in the mouse brain (Figure 2A,B) with proliferation
indices of 34 +/− 2% as determined by Ki67 IHC staining
(Figure 2C and not shown). Apoptotic cells, as determined
by IHC for activated caspase 3A, were hardly detected
(<0.1%; data not shown). Blood vessels were often abnormal
with signs of endothelial hyperplasia and microvascular pro-
liferation with prominent CD34 staining (Figure 2D), remin-
iscent of typical high grade glioma pathology. The presence
of extravascularly deposited mouse IgG indicated focal dis-
ruption of the blood brain barrier (BBB; Figure 2E). The
tumor vasculature was positive for the BBB-marker GLUT-
1 throughout the tumor (Figure 2F). However, tumor cell-
associated GLUT-1 or monocarboxylate transporters
MCT1 and MCT4 were not present (Figure 2F and data
not shown). The absence of these HIF1α-regulated hyp-
oxia markers is in accordance with recent studies that
show an inhibition of HIF1α expression induced by D-
2HG and EGLN in IDH1-mutant tumor cells [33,34].
A B C
D E F
Figure 2 Phenotypic characteristics of the IDH1 mutant xenograft model. Low (A) and high (B) magnifications of H&E-stained sections of
E478 xenografts in mouse brain, showing diffuse infiltration throughout both hemispheres (note that infiltrative strands of cancer cells are
interspersed in white matter [B]). C) Ki-67 staining resulted in a proliferation index of approximately 34%. D) Immunohistochemical anti-CD34
staining shows abundant presence of florid microvascular proliferations. E) Immunostaining of mouse IgG shows limited and focal leakage of IgG
from the tumor vasculature. The arrowhead in the low-magnification inset indicates the area depicted. F) Blood vessels in the tumor express
GLUT-1 that is characteristic for endothelial cells forming the blood–brain barrier. Cancer cells do not express GLUT-1, indicating that the tumor is
not hypoxic. Size bars in A: 1 mm, B-F 100 μm.
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Figure 3 (See legend on next page.)
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D-2HG production in E478 xenografts
D-2HG levels were determined in extracts of E478
xenografts using liquid chromatography coupled to
mass spectrometry (LC-MS) [24]. E478 tumor ex-
tracts contained highly elevated levels of D-2HG
(34.5 nmol/mg protein vs < 0.2 nmol/mg protein in
IDH1-wt E434 xenografts; n = 3, p < 0.0001; Figure 3A).
D-2HG levels in plasma of tumor-bearing mice were
not altered (data not shown) which is in agreement
with the recent finding that plasma levels of D-2HG
do not correlate with IDH1-mutation status in glioma
patients [46].
D-2HG levels in the brain extracts used in our LC-MS
measurements varied highly (Figure 3A), a likely conse-
quence of variations in tumor/stroma ratios in the
extracts. To more reliably determine spatial D-2HG
production in E478 xenografts, we used Quantinetix
technology which allows sensitive and quantitative mea-
surements of metabolites in situ in tissue sections using
Liquid Extraction Surface Analysis (LESA) coupled to
High Resolution Electrospray Mass Spectrometry (HR-
ESI-MS) (Figure 3B). Our measurements were performed
in spots with a size of 0.12 mm2. Concentrations were
expressed as heat maps, superimposed on histologically
stained sections (Figure 3B). D-2HG levels were in-
creased in tumor tissue only (60–820 μg D-2HG/g
tissue; Table 1), while much lower concentrations of the
metabolite were detected in non-tumor brain areas and
in healthy mouse brain. In line with the LC-MS mea-
surements, the difference in D-2HG levels between
IDH1-mutant tumors and normal brain was over 100-
fold (3.1 vs 0.02 nmol/mg; Table 1). We also found
significantly elevated levels of D-2HG in IDH1-wt glio-
blastoma xenografts as compared to normal brain, al-
though the levels were lower than in IDH1-mutant
tumors (approximately 10-fold difference: 3.1 vs 0.33
nmol/mg). Indeed, it has been shown that wtIDH1 can
convert α-KG to D-2HG. However, this reaction is ham-
pered by competitive displacement of α-KG by isocitrate
in the catalytic site under normal conditions [36]. A low
isocitrate/α-KG ratio may thus result in D-2HG produc-
tion as well.
(See figure on previous page.)
Figure 3 D-2HG and α-KG levels in xenografts. A) D-2HG levels in extracts of xenograft-containing mouse brains from E478 IDH1-mutant and
E434 IDH-wild type (wt) tumors as detected by LC-MS. B) In situ detection of D-2HG and α-KG levels in tumor sections using LESA-nano ESI-FTICR.
Upper panel shows H&E stained sections of mouse brain (pink) with tumors (blue) from which tissue plugs were analysed. Lower panels show
Quantinetix views of tissue plugs for 2-HG (m/z 147.032) and α-KG (m/z 145.017) respectively. C) Quantification of D-2HG and α-KG levels in
individual tissue plugs taken from control brain, IDH1-mutant xenografts and IDH-wt xenografts. Sample numbers encircled in blue represent
tissue plugs as shown in (B). D) Mean D-2HG and α-KG levels in control brain (ctr B), IDH1-mutant xenografts (m IDH) and IDH-wildtype
xenografts (wtIDH). Note the difference in scale of the Y-axes in these graphs. Levels of α-KG were very low as compared to D-2HG levels, but
clearly detectable in all plugs.
Table 1 D-2HG and αKG levels in individual spots in
sections of othotopic xenografts carrying the
IDH1-R132H mutation (italic) or wild-type IDH
Spot number D-2-HG (μg/g) α-KG (μg/g)
1 0.0 0
2 4.7 11.2
3 2.9 5.2
4 6.5 17.2
5 4.7 5.2
6 8.3 11.2
7 4.7 17.2
8 66.7 52.9
9 311 35
10 819.8 0
11 653.9 17.2
53 650.2 17.2
54 194.3 5.2
14 0 0
15 0 5.2
18 358.4 17.2
17 254.5 17.2
16 312.9 5.2
19 4.7 23.1
20 6.5 5.2
21 37.5 41
22 63 82.7
23 39.3 41
24 4.7 5.2
25 4.7 17.2
26 6.5 17.2
27 15.6 11.2
28 46.6 35
29 17.4 17.2
30 88.6 52.9
Spots 1-6 represent normal brain.
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In line with previous observations [24] we detected
similar levels of α-KG in all tumor samples, both IDH1-
mutant and -wt. There was a tendency towards higher
levels in tumors compared to normal brain, although the
levels were not significantly different. These findings
suggest that the α-KG pool is maintained at physio-
logical levels despite its depletion by conversion into D-
2HG in the IDH1-mutant tumor.
In summary we show that in IDH1-mutant xenografts
D-2HG levels are approximately 100-fold higher as com-
pared to normal brain tissue and that these high levels
are restricted to the tumor area. Moreover, α-KG levels
are maintained at physiological levels in these tumors.
NAD+- and NADP+-dependent dehydrogenase activity in
E478 tumors
IDH1-R132H expression is expected to result in diminished
levels of α-KG in the cytosol. Since we did not observe
detectable decreases in total cellular a-KG levels, we ar-
gued that E478 cells may depend on mitochondrial
IDHs to generate α-KG for cytosolic use. To test this,
10 μm-thick cryostat sections of E478 and E434
oligodendroglioma xenografts were subjected to metabolic
mapping to stain activity of NAD+- and NADP+-dependent
IDHs and succinate dehydrogenase (SDH), as a read-out
for mitochondrial activity. While E434 xenografts show-
ed low activity of SDH and NAD+-dependent IDH
(Figure 4A,C), the activities of these enzymes were much
more prominent in E478 xenografts (Figure 4B,D). Al-
though NADP+-dependent IDH activity was higher than
NAD+-mediated IDH activity in both xenografts (compare
E,F to C,D), this increase was far more distinct in E478 xe-
nografts (Figure 4F). The high NADP+-dependent IDH ac-
tivity in E478 suggests that the cancer cells compensate the
IDH1 defect by upregulating the activity of the mitochon-
drial IDH2.
To further investigate the high mitochondrial activity
in E478, we performed transmission electron microscopy
on a panel of glioma xenografts. Measurement of
mitochondrial densities revealed a 2-fold increase in the
number of mitochondria in the IDH1-mutant E478
tumor cells as compared to those in E434 anaplastic
oligodendroglioma and the E98 glioblastoma xenograft
lines (Figure 5A-C).
E434 (IDH1-wt)
IDH-NAD+
dependent
E478 (IDH1-R132H)
SDH
A
C
IDH-NADP
dependent
E
B
D
F
Figure 4 Metabolic mapping. Localization of activity of SDH (A,B), NAD+-dependent IDH (C,D) and NADP+-dependent IDH (E,F). The blue color
represents the activity of the respective dehydrogenases after 15 minutes of incubation at 37°C. Note the high activities of mitochondrial
dehydrogenases in E478 xenograft as compared with the E434 xenograft. Bar = 100 μm.
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Discussion
We here present a detailed histologic and metabolic
characterization of the E478 IDH1-R132H mutant oligo-
dendroglioma xenograft line, the development of which
has been described before [41]. This line was established
already in 2005, before the recognition of the involve-
ment of IDH1/2-mutations in gliomagenesis. The E478
xenograft line has been grown successfully for over 35
passages now, is genetically stable and produces elevated
levels of the oncometabolite D-2HG.
It is still not completely understood how IDH1 muta-
tions in gliomas contribute to tumorigenesis and at the
same time are correlated to good prognosis as compared
to gliomas with wtIDH [21,47]. Likely, the effects are
multifactorial. Elevated D-2HG levels have been proposed
to result in a block of differentiation via epigenetic alter-
ations [30], including the induction of a hypermethylated
DNA phenotype [35]. Hypermethylation of genes encod-
ing DNA repair enzymes such as MGMT is a predictor for
the response to alkylating chemotherapy [48]. However
prognosis of patients with IDH1 mutated glioma is not
confined to those receiving chemotherapy, suggesting that
other factors may also be important. Models such as the
E478 xenograft may contribute to elucidate the underlying
mechanisms of IDH mutations with respect to glioma-
genesis and prognostic relevance. Our data indicate that
some answers may be found in the field of tumor
metabolism as we observed mitochondrial hyperactivity in
E478 xenografts. It remains unfortunate that only a lim-
ited number of endogenous IDH1-R132H mutant glioma
models is currently available [38,40] making it difficult to
confirm our findings in other models.
We found that NADP+-dependent isocitrate conver-
sion was not decreased in E478 xenografts as compared
to IDHwt glioma, indicating that cells compensate for
loss of IDH1 activity by increasing mitochondrial IDH2
activity by inducing mitochondrial biosynthesis. This is
in agreement with our finding that α-KG levels are not
diminished in E478 xenografts as compared to IDHwt
tumors. These data suggest that D-2HG, rather than a
shortage of α-KG, is involved in the specific features of
IDH1-mutated glioma and is in line with D-2HG-medi-
ated competition of α-KG dependent enzymes. Yet, our
measurements do not allow discrimination between mito-
chondrial and cytosolic α-KG levels, and a role for a spe-
cific depletion of the cytosolic pool of α-KG in tumor
biology cannot be excluded. For instance, fatty acid syn-
thesis is an essential condition for tumor growth, and re-
quires cytosolic α-KG and acetyl-CoA as precursors [49].
Depletion of cytosolic α-KG may compromise lipid bio-
synthesis and might require import of mitochondrial α-
KG into the cytosol. An attractive hypothesis is that such
processes require a lot of energy for cell survival at the ex-
pense of extensive tumor cell proliferation. This may be a
A B
C
Figure 5 Transmission electron microscopy. Transmission electron microscopical micrographs of the increased mitochondrial density in E478
(A) as compared to E434 xenografts (B). C) Quantification of mitochondrial densities in IDHwt E98 and E434 xenografts and IDH1-R132H
E478 xenografts).
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possible explanation for the better prognosis of patients
with IDH-mutated gliomas.
An alternative manner to deal with decreased cytosolic
α-KG, apart from increasing IDH2 activity, may be in-
creased import of glutamine via specific importers in gli-
oma cells. Glutaminase converts glutamine to glutamate
which is subsequently converted to α-KG by glutamate
dehydrogenase [50]. This metabolic adaptation may be
in line with the increased dependency of IDH1-mutant
gliomas on exogenous glutamine, the low levels of glu-
tamate in IDH1-mutant gliomas [51] and the sensitivity
of these tumors to glutaminase inhibitors [52]. The rela-
tive contribution of these systems in α-KG homeostasis
remains to be determined.
It is still enigmatic why mutations in IDH genes are
only found in the NADP+-dependent enzymes. It is
tempting to speculate that this is related to a specific as-
pect of NADP+ metabolism. During conversion of α-KG
to D-2HG by IDH1-R132H, NADPH is oxidized to
NADP+ and is not available for generation of reduced
glutathione and other detoxifying systems [53]. As re-
duced glutathione is essential for scavenging reactive oxy-
gen species (ROS), this may result in increased oxidative
stress in IDH1-mutant glioma cells, a phenomenon that
will be further augmented by increased mitochondrial
density. Indeed, glutathione levels appear to be lower in
IDH1-mutated tumors [51]. How IDH1-mutant tumors
cope with this stress is currently under investigation in
our laboratory.
Based on our findings we propose that tumor cells that
carry the IDH1 mutation undergo a metabolic switch in-
volving increased mitochondrial activity leading to
impaired proliferation and a relatively good prognosis.
Cells acquiring IDH1 mutations will become tumori-
genic based on the oncogenic activity of D-2HG, pos-
sibly in combination with acquired mutations in TP53
[34,54]. Acquiring IDH1 mutations comes at a price
however, as it will pose the cell with an excessive need
for exogenous sources of α-KG for sustained membrane
synthesis. The increased requirement for α-KG results in
an increased dependency on exogenous glutamine. Inter-
estingly, glutamine is produced at high levels by glial
cells and is under normal conditions used by neurons as
a precursor for the neurotransmitter glutamate. It would
be interesting to investigate whether the dependency on
glutamine or glutamate as external carbon source has a
causal relation to the diffuse infiltrative growth in
neuroglial tissue that is characteristic of diffuse gliomas.
Indeed, such a dependency suggests that tumor cells
would benefit from the nearby presence of non-
neoplastic glial cells or neurons.
This model thus provides novel handles for metabolic
targeting of low grade gliomas. Especially inhibition of
glutaminolysis may be an effective way to interfere with
glioma metabolism, although the effects of such an
intervention on neuronal glutamate function will require
careful evaluation. Combination approaches to further
increase redox stress and/or glycolysis may further arrest
tumor cells.
Conclusions
The E478 xenograft line represents a stable tumor model
with the endogenous IDH1-R132H mutation. We show
that this model has high mitochondrial activity, produces
high levels of D-2HG and maintains near-physiological
levels of α-KG. We propose that this model will be of
high value for investigating novel therapies for the large
group of gliomas that carry IDH1-R132H mutations.
Methods
Intracranial xenografting
Athymic female BALB/c nu/nu mice (18–25 gram, age
6–8 weeks) were kept under specified pathogen-free
conditions and received food and water ad libitum. The
local Animal Experimental Committee of the Radboud
University Nijmegen Medical Centre approved all exper-
iments. Glioma cell suspensions, directly obtained from
surgically resected tumor tissue of a patient with an ana-
plastic oligodendroglioma, which was later shown to
carry the IDH1-R132H mutation, were injected intracra-
nially as described previously [41]. Animals were closely
monitored and sacrificed when evident signs of tumor
burden (especially weight loss >15% in two days, severe
neurological abnormalities) were observed. The xeno-
graft line has been maintained by direct intracerebral
passaging of tumor cell suspensions, generated from
E478-bearing mouse brains as described [41].
Cryopreservation of xenograft brains
To test whether E478 cancer cells retain their tumorigenic
potential upon cryopreservation, cell suspensions of
tumor-bearing brains were generated in PBS and washed
twice followed by suspension in DMEM (containing 0.45%
w/v glucose; PAA Laboratories, Pasching, Austria) with
5% DMSO (Merck, Nottingham, UK). Cell suspensions
were frozen at −1°C/min in Nalgene Mr. Frosty containers
(ThermoScientific, Landsmeer, The Netherlands) at −80°C
and subsequently stored in liquid nitrogen for at least a
month. For re-injection, cells were rapidly thawed at 37°C,
washed twice and suspended in PBS, followed by intracra-
nial injection in mice (n = 5) as described above. When
animals developed tumor-related symptoms, a tumor of
one of the mice was transplanted into new animals (n = 5).
Array comparative genomic hybridization (aCGH)
aCGH was carried out with DNA of the originating pa-
tient tumor and several passages of the derived xeno-
grafts. DNA was digested using the restriction enzymes
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RsaI and AluI, followed by labeling using the Bio Prime
CGH Genomic Labeling Kit (Invitrogen, Carlsbad, CA)
and Cy3 and Cy5 dyes (GE Healthcare, Buckinghamshire,
UK), according to standard protocols for Agilent CGH.
Commercially available female DNA pooled from multiple
donors (Promega Cat:G1521) was used as reference. La-
beled DNA was competitively hybridized to SurePrint G3
Human 2×400k CGH microarrays (G4448A, Agilent
Technologies, Amstelveen, The Netherlands) following
standard protocols. The slides were scanned at 3 μm reso-
lution using the Agilent High-Resolution Microarray
scanner and the image data were extracted with Feature
Extraction software (Agilent Technologies). Feature ex-
traction files were imported into Genomic Workbench 7.0
for visualization and analysis. Briefly, after diploid
centralization and GC correction, aberrations were called
using the ADM2 algorithm with a threshold setting of 20,
centralization on with a threshold of 25 and an aberration
filter min Probes = 5 and minAvgAbsLogRatio = 0.25 for
amplifications and deletions.
Immunohistochemistry (IHC)
Animals with tumor-related symptoms were sacrificed
by cervical dislocation and brains were removed for fix-
ation in buffered formalin and subsequent paraffin em-
bedding. Parts were also snap frozen in liquid nitrogen
and stored for protein analysis and DNA/RNA isolation,
D-2HG measurements and metabolic mapping.
H&E and immunohistochemical stainings were per-
formed as described previously [55] including the use of
antibodies directed against IDH1-R132H (clone H09,
Dianova, Hamburg, Germany), Ki67 (for proliferation
index assessment, clone Sp6, Neomarkers, Fremont, CA),
cleaved caspase 3A (for detection of apoptotic cells, clone
C92-605, BD Pharmingen, Franklin Lakes, NJ), CD34 (for
endothelial cell staining, clone MEC14.7, Hycult Biotech,
Uden, The Netherlands), GLUT-1 (Neomarkers), mouse
IgG (Vector, Burlingame, CA), MCT-1 and MCT-4
(clones C-20 and H-90 respectively, Santa Cruz, CA).
Primary antibody incubations were performed using 4
μm-thick sections of formalin-fixed paraffin-embedded
tumor samples. Appropriate biotinylated secondary
antibodies were used for detection using the ABC-
method (Vector Laboratories). Specific signals were vi-
sualized by staining with 3-amino-9-ethyl-carbazole
(Scytek Laboratories, West-Logan, Ut). All sections
were counterstained with haematoxylin and mounted in
Imsol Mount medium (Klinipath B.V., Duiven, The
Netherlands). For all stainings, control incubations were
carried out by omitting the primary antibody.
Metabolic mapping
Activities of NADPH- and NADH-producing dehydroge-
nases were visualized using metabolic mapping [53,56]
using 10 μm thick unfixed cryostat sections of mouse
brains infiltrated with E478, E434 or E98 glioblastoma
xenografts [41]. The wt IDH1 status of E434 and E98 xeno-
graft lines (oligodendroglioma and glioblastoma, respect-
ively) was previously confirmed. Control incubations to
establish the specificity of the enzyme reactions, were
performed in the absence of relevant substrates [53,56].
Electron microscopy
Tissue samples of approximately 1–2 mm3 were fixed in
2% glutaraldehyde in cacodylate buffer (100 mM) for 4
hours, rinsed in cacodylate buffer and post-fixed for 1 hour
in a solution of 1% osmium tetroxide containing 1% potas-
sium hexacyanoferrat. Semithin (1 μm) sections and
ultrathin (70 nm) sections were cut on an ultramicrotome
(Leica EM UC6). Semithin sections were stained with
toluidin blue for light microscopical previewing and
ultrathin sections were collected on 200 mesh copper grids
and contrasted with uranyl acetate and lead citrate. All sec-
tions were examined and images generated on a JEM1200
transmission electron microscope (Jeol, The Netherlands).
D-2HG measurements by isotope dilution LC-MS
D-2HG levels in serum and tissue extracts were mea-
sured using stable isotope dilution liquid chromatog-
raphy tandem mass spectrometry (LC-MS). D-2HG for
the preparation of calibration standards was purchased
from Sigma Aldrich. Samples of 100 μl were mixed with
50 μl of 13C5-2-HG stable isotope solution (Chiralex,
Nijmegen, The Netherlands; 10 μM in deionized water)
before passing it through a Microcon YM-30 filter
(Millipore) by centrifugation (14,000xg; 30 min). After
acidification of the filtrate with 10 μl 4% formic acid in
deionized water, 5 μl was injected into a Luna PFP col-
umn (2.1 mm*100 mm*3 μm, Phenomenex). The mobile
phase consisted of methanol and water containing 0.3%
formic acid. 2-HG was separated from its isomers 3-
hydroxyglutarate and 2-hydroxy-2-methylsuccinate using
a water-to-methanol gradient at 250 μl/min. The column
was connected to an electrospray tandem mass spectrom-
eter (Quattro LC, Micromass) operated in negative mode
(capillary voltage 3 kV, cone voltage 20V) with an argon
filled collision cell (0.18 Pa, 9eV). The tandem mass
spectrometer was set to monitor the water loss of both
D-2HG and 13C5-2-HG recording the mass transitions of
m/z 147 to 129 and m/z 152 to 134, respectively. The
temperature settings for the source and ion block were
400°C and 100°C respectively. Nitrogen was used as drying
and nebulizer gas set at flow rates of respectively 650 L/h
and 100 L/h.
In situ metabolite quantification by LESA-nano ESI-FTICR
In a separate set of experiments, we quantified D-2HG
and α-KG levels via LESA (Liquid Extraction Surface
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Analysis, Nanomate, Advion) coupled to ESI-FTICR
(Fourier transform ion cyclotron resonance, Solarix 7T,
Bruker Daltonics, Bremen) and Quantinetix Software
(ImaBiotech, France) allowing very sensitive detection
and quantification of metabolites in small tissue plugs
taken from 10 μm thick cryostat brain sections (Cryostat
HM560, Microme). The Nanomate system was used in
LESA mode with a 400 μm diameter surface extraction.
Sample plates were cooled down to 12°C during ana-
lyses. Spray parameters were set as follows: Voltage to
apply 1.30 kV and gas pressure 0.40 psi. Extraction solvent
consisted of 65:15:20 MeOH:IPA:Water + 5 mM ammo-
nium acetate using LCMS quality solvents. 0.6 μL extrac-
tion solvent was used to extract analytes from the surface
and was injected then into the nano-electrospray source.
Tissue suppression was calculated using Quantinetix to
address matrix effect and to normalize signals of 2-HG
and α-KG. A dilution range of pure metabolites mixed
with brain tissue was applied next to the samples for abso-
lute quantification and data for each LESA spot were ana-
lyzed using Quantinetix™ (ImaBiotech, France) taking 10
mDa mass tolerance around theoretical m/z of 2-HG and
α-KG. Data were normalized against a standard included
in the extraction solvent (m/z 141.019). Mass spectrom-
etry was performed using the negative mode with the
nano-electrospray source and CASI mode (isolation of
m/z 150 +/− 50 Da in the quadrupole) in the mass range
71–160 Da. Each acquisition was a result of 80 accumu-
lated spectra.
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